```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  AUG 09  INSPEC enhanced with 1898-1968 archive
 NEWS  4  AUG 28  ADISCTI Reloaded and Enhanced
 NEWS  5  AUG 30  CA(SM)/CAplus(SM) Austrian patent law changes
 NEWS  6  SEP 11  CA/CAplus enhanced with more pre-1907 records
 NEWS  7  SEP 21  CA/CAplus fields enhanced with simultaneous left and right
                  truncation
 NEWS  8  SEP 25  CA(SM)/CAplus(SM) display of CA Lexicon enhanced
 NEWS  9  SEP 25  CAS REGISTRY(SM) no longer includes Concord 3D coordinates
 NEWS 10  SEP 25  CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
 NEWS 11  SEP 28  CEABA-VTB classification code fields reloaded with new
                  classification scheme
 NEWS 12  OCT 19  The Derwent World Patents Index suite of databases on STN will
                  be enhanced and reloaded on October 22, 2006
 NEWS 13  OCT 19  LOGOFF HOLD duration extended to 120 minutes
 NEWS 14  OCT 19  E-mail format enhanced

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:41:03 ON 23 OCT 2006

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.42       0.42

FILE 'REGISTRY' ENTERED AT 09:42:05 ON 23 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 OCT 2006 HIGHEST RN 911002-75-0
DICTIONARY FILE UPDATES: 22 OCT 2006 HIGHEST RN 911002-75-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\107135001.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19
ring nodes :
1 2 3 4 5
chain bonds :
9-10 10-11 11-12 11-19 12-13 13-14 15-16 16-17 17-18
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
9-10 10-11 11-12 11-19 12-13 13-14 15-16 16-17 17-18
exact bonds :
1-2 1-5 2-3 3-4 4-5
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS

L1   STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:42:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    11933 TO ITERATE

 16.8% PROCESSED     2000 ITERATIONS                                0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       232115 TO   245205
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:42:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   239225 TO ITERATE

100.0% PROCESSED   239225 ITERATIONS                              34 ANSWERS
SEARCH TIME: 00.00.06

L3            34 SEA SSS FUL L1

=> s l3 and caplus/lc
      52459624 CAPLUS/LC
L4           34 L3 AND CAPLUS/LC

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               171.70     172.12

FILE 'CAPLUS' ENTERED AT 09:42:53 ON 23 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Oct 2006 VOL 145 ISS 18
FILE LAST UPDATED: 22 Oct 2006 (20061022/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l4
L5 15 L4

=> d ibib abs hitstr 1-15

L5 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:364394 CAPLUS
DOCUMENT NUMBER: 144:382488
TITLE: Novel prostamides for the treatment of glaucoma and related diseases
INVENTOR(S): Woodward, David F.; Burk, Robert M.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041875	A1	20060420	WO 2005-US35748	20051004

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-616780P P 20041006

OTHER SOURCE(S): MARPAT 144:382488

AB Disclosed herein are compns. comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compds., pharmaceutical compns., and methods of treating glaucoma.

IT 851727-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prostamides for the treatment of glaucoma and related diseases)

RN 851727-22-5 CAPLUS
CN Prosta-5,13-dien-1-amide, 9,11,15-trihydroxy-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L5 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:431411 CAPLUS
DOCUMENT NUMBER: 142:457143
TITLE: Novel prostamides for the treatment of glaucoma and related diseases
INVENTOR(S): Woodward, David F.; Burk, Robert M.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005107463	A1	20050519	US 2003-713500	20031113
AU 2004291507	A1	20050602	AU 2004-291507	20041108
CA 2546013	AA	20050602	CA 2004-2546013	20041108
WO 2005049558	A1	20050602	WO 2004-US37437	20041108

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1682498	A1	20060726	EP 2004-810636	20041108

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

PRIORITY APPLN. INFO.: US 2003-713500 A 20031113
WO 2004-US37437 W 20041108

OTHER SOURCE(S): MARPAT 142:457143

GI



I

AB Disclosed are compns. comprising an amide related to a prostaglandin and an amine wherein the amine is selected from the group consisting of epinephrine, dopamine, serotonin, and analogs or prodrugs thereof. E.g., I and its hydrolyzed benzenediol derivative as well as an indole derivative were prepared and tested for effect on intraocular pressure in dogs. Thus, the

L5 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

compds. can be used in the treatment of glaucoma.

IT 851727-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prostamides preparation for the treatment of glaucoma and related diseases)

RN 851727-22-5 CAPLUS
CN Prosta-5,13-dien-1-amide, 9,11,15-trihydroxy-N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L5 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:33807 CAPLUS
DOCUMENT NUMBER: 110:33807
TITLE: Electroimmunoassay of PGE2: an antibody-sensitive electrode based competitive protein-binding assay
AUTHOR(S): Connell, George R.; Sanders, Kenton M.
CORPORATE SOURCE: Sch. Med., Univ. Nevada, Reno, NV, 89557, USA
SOURCE: Electrochem. Sens. Immunol. Anal. (1987), 35-45. Editor(s): Ngo, That Tjien. Plenum: New York, N. Y. CODEN: 56KEAX
DOCUMENT TYPE: Conference
LANGUAGE: English

AB A technique is described in which an antibody-sensitive electrode for anti-PGE2 antisera was used to measure solution-phase PGE2 in nanomolar quantities. The electrode was constructed by incorporating a cation-selective ionophore-hapten (PGE2) conjugate into a polyvinyl chloride membrane. Transmembrane potential in a fixed K gradient was measured. The addition of anti-PGE2 antisera changed membrane potential in a concentration-dependent manner. The effect of anti-PGE2 antibodies on membrane potential was decreased by adding free PGE2 to the buffer containing antisera. With this technique a competitive protein-binding assay was developed and standard curves for solution-phase PGE2 were generated over a concentration range of 1-1000 nM. The assay was relatively specific for PGE2; PGD2 and PGF2α had only minor effects on transmembrane potential over the effective concentration range for PGE2.

IT 87725-47-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 87725-47-1 CAPLUS
CN Prosta-5,13-dien-1-amide, N,N'-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2,13-diyl)bis[11,15-dihydroxy-9-oxo-, (5Z,11α,13E,15S)-(5'Z,11'α,13'E,15'S)- (9CI) (CA INDEX NAME)

PAGE 1-A



L5 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C

L5 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1985:541728 CAPLUS
DOCUMENT NUMBER: 103:141728
TITLE: 5-Azaprostacyclin derivatives and their therapeutic use
INVENTOR(S): Raduechel, Bernd; Skuballa, Werner; Vorbrueggen, Helmut; Loge, Olaf; Haberey, Martin; Stuerzebecher, Claus Steffen
PATENT ASSIGNEE(S): Schering A.-G. , Fed. Rep. Ger.
SOURCE: Ger. Offen., 22 pp. CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3320014	A1	19841206	DE 1983-3320014	19830601
PRIORITY APPLN. INFO.:			DE 1983-3320014	19830601

GI



I

II



III

AB Title compds. I (n = 2-5; R = acid, ester, or acetal group, R1 = H or Me; Z, Q, A, R2 = groups associated with prostaglandins) were prepared Thus, the lactone II was aminolyzed with H2N(CH2)3CO2Et, mesylated, and hydrolyzed in two steps to give the aza analog III.

IT 97715-66-7
RL: PROC (Process)
(partial deprotection of)
RN 97715-66-7 CAPLUS
CN Cyclopentaneacetamide, 2-[3-(1-butylcyclobutyl)-3-hydroxy-1-propenyl]-N-[3-(5,5-dimethyl-1,3-dioxan-2-yl)propyl]-3-hydroxy-5-[(methylsulfonyl)oxy]-, [1R-[1α,2β(1E,3R*),3α,5α]]- (9CI) (CA INDEX NAME)

L5 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



L5 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:622820 CAPLUS
DOCUMENT NUMBER: 101:222820
TITLE: Design of ionophore hapten conjugates for electroimmunoassay
AUTHOR(S): Connell, G. R.; Sanders, K. M.
CORPORATE SOURCE: Sch. Med., Univ. Nevada, Reno, NV, 89557, USA
SOURCE: Proceedings of the Western Pharmacology Society (1984), 27, 337-40
CODEN: PWPSA8; ISSN: 0083-8969
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The preparation of the ionophore hapten conjugate, PGE2 trans-diamide of dibenzo-18-crown-6 (I) [87725-47-1] for use as a PGE2 [363-24-6] antibody sensitive electrodeis described. The preparation consisted of dibenzo-18-crown-6 [14187-32-7] nitration, separation of the cis and trans-dinitro products, reduction to the trans-diamine form, and coupling to a mixed anhydride containing PGE2 in CH3CN. The mixed anhydride of PGE2 is formed by mixing Et chloroformate with PGE2 triethylamine salt. Antibody sensitive membranes were prepared by dissolving 1 mg I in 5 mL THF with 250 μL di-Bu sebacate as a plasticizer. The mixture was poured into a 50 mm petri dish containing 250 mg Cl- and the solvent allowed to evaporate; resulting in the formation of a flexible membrane 0.2 mm thick. A hypothetical interaction between fixed PGE2 mols. conjugated to the membrane bound ionophore, I, and anti-PGE2 antibodies and the effects of free PGE2 on the system in a fixed K+ gradient is shown. As the concentration of free PGE2 increases, antibody mols. are displaced from the membrane resulting in a reduction in the voltage response caused by antibody. Conjugate design for EIA also discussed.
IT 87725-47-1P
RL: SPN (Synthetic preparation); PREP (Preparation)

L5 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of, for electroimmunoassay)
RN 87725-47-1 CAPLUS
CN Prosta-5,13-dien-1-amide, N,N'-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2,13-diyl)bis[11,15-dihydroxy-9-oxo-, (5Z,11α,13E,15S)-(5'Z,11'α,13'E,15'S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C

L5 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1984:103046 CAPLUS
DOCUMENT NUMBER: 100:103046
TITLE: Optically active or racemic prostaglandin derivatives and a pharmaceutical agent containing them
INVENTOR(S): Faustini, Franco; Villa, Vittoria; Gandolfi, Carmelo; Di Salle, Enrico
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Italy
SOURCE: Ger. Offen., 90 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3241399	A1	19830601	DE 1982-3241399	19821109
DE 3241399	C2	19901031		
US 4543353	A	19850924	US 1982-436419	19821025
CH 656877	A	19860731	CH 1982-6213	19821025
AU 8289797	A1	19830602	AU 1982-89797	19821026
AU 552847	B2	19860626		
ZA 8207825	A	19830831	ZA 1982-7825	19821026
IL 67103	A1	19861130	IL 1982-67103	19821028
HU 27906	O	19831128	HU 1982-3479	19821029
HU 188600	B	19860428		
FR 2517302	A1	19830603	FR 1982-18434	19821103
FR 2517302	B1	19841214		
CA 1237718	A1	19880607	CA 1982-414934	19821104
AT 8204214	A	19901215	AT 1982-4214	19821118
AT 392964	B	19910725		
FI 8204017	A	19830528	FI 1982-4017	19821123
FI 77442	B	19881130		
FI 77442	C	19890310		
BE 895137	A1	19830525	BE 1982-209565	19821125
SE 8206731	A	19830528	SE 1982-6731	19821125
SE 454588	B	19880516		
SE 454588	C	19880825		
SU 1301309	A3	19870330	SU 1982-3515155	19821125
DK 8205289	A	19830528	DK 1982-5289	19821126
NL 8204611	A	19830616	NL 1982-4611	19821126
JP 58103356	A2	19830620	JP 1982-206282	19821126
JP 03069899	B4	19911105		
GB 2111986	A1	19830713	GB 1982-33732	19821126
GB 2111986	B2	19850515		
SU 1321372	A3	19870630	SU 1984-3697654	19840131
PRIORITY APPLN. INFO.:			GB 1981-35799 A	19811127

OTHER SOURCE(S): MARPAT 100:103046
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Esters and amides of overall structure I (especially R = (un)substituted amino or R1CH2CH2 (R1 = EtO, Me2N, piperidino, morpholino); R2 - R9 were groups associated with prostaglandins; m = 0-3] were prepared (.apprx.150 in all).

L5 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Typical of compds. prepd. were II - IV.
IT 87303-42-2P 87303-47-7P 87332-25-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 87303-42-2 CAPLUS
CN 5-Heptenamide, 7-[2-(5-cyclohexyl-4-fluoro-3-hydroxy-1-pentynyl)-3,5-dihydroxycyclopentyl]-N-(1-piperazinylmethylene)-, hydrochloride, [1R-[1α(Z),2β(3R*,4S*),3α,5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



●x HCl

RN 87303-47-7 CAPLUS
CN 5-Heptenamide, 7-[2-(5-cyclohexyl-4-fluoro-3-hydroxy-1-pentynyl)-3,5-dihydroxycyclopentyl]-N-(1-piperazinylmethylene)-, hydrochloride, [1R-[1α(Z),2β(3S*,4S*),3α,5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



●x HCl

RN 87332-25-0 CAPLUS
CN 5-Heptenamide, 7-[2-(5-cyclohexyl-4-fluoro-3-hydroxy-1-pentynyl)-3,5-

L5 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dihydroxycyclopentyl]-N-(1-piperazinylmethylene)-, [1R-[1α(Z),2β(3R*,4S*),3α,5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



IT 87228-99-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, and HCl salt preparation from)
RN 87228-99-7 CAPLUS
CN 5-Heptenamide, 7-[2-(5-cyclohexyl-4-fluoro-3-hydroxy-1-pentynyl)-3,5-dihydroxycyclopentyl]-N-(1-piperazinylmethylene)-, [1R-[1α(Z),2β(3S*,4S*),3α,5α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.



L5 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:587901 CAPLUS
DOCUMENT NUMBER: 99:187901
TITLE: Electroimmunoassay. A new competitive protein-binding assay using antibody-sensitive electrodes
AUTHOR(S): Connell, George R.; Sanders, Kenton M.; Williams, Roy L.
CORPORATE SOURCE: Sch. Med., Univ. Nevada, Reno, NV, 89557, USA
SOURCE: Biophysical Journal (1983), 44(1), 123-6
CODEN: BIOJAU; ISSN: 0006-3495
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB An antibody-sensitive electrode for anti-prostaglandin E2 antisera was used to measure solution-phase PGE2 (I) [363-24-6] in nanomolar quantities.
The electrode was constructed by incorporating a cation-selective ionophore-hapten (PGE2) conjugate into a polyvinyl chloride membrane. Transmembrane potential in a fixed K+ gradient was measured. The addition of
anti-PGE2 antisera changed membrane potential in a concentration-dependent
manner. The effect of anti-PGE2 antibodies on membrane potential was decreased by adding free PGE2 to the buffer-containing antisera. With this
technique a competitive protein-binding assay was developed, and standard curves for solution-phase PGE2 were generated over a concentration range of 1-1000
nM. The assay was relatively specific for PGE2; PGD2 [41598-07-6] and PGF2α [551-11-1] had only minor effects on transmembrane potential over the effective concentration range for PGE2.
IT 87725-47-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 87725-47-1 CAPLUS
CN Prosta-5,13-dien-1-amide, N,N'-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2,13-diyl)bis[11,15-dihydroxy-9-oxo-, (5Z,11α,13E,15S)-(5'Z,11'α,13'E,15'S)- (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C

L5 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:516255 CAPLUS
DOCUMENT NUMBER: 99:116255
TITLE: Sensitivity and specificity of eicosanoid radioimmunoassays: new strategy
AUTHOR(S): Dray, F.
CORPORATE SOURCE: INSERM, Inst. Pasteur, Paris, 75724/15, Fr.
SOURCE: British Journal of Dermatology (1983), 109(Suppl. 25), 36-40
CODEN: BJDEAZ; ISSN: 0007-0963
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Eicosanoids were coupled with histamine and radioiodinated by the iodogen method for use in RIA. The iodinated derivs. could be stored >6 mo after high-performance liquid chromatog. purification RIA's using 13 tritiated and
iodinated prostanoid tracers were compared. With iodinated tracers the final determination of antiserums of the eicosanoids was always higher than that
with tritiated tracers and sensitivity was increased. The concns. of 6-keto-PGF1α and 6,15-diketo-PGF1α in human plasma, serum, and urine and in rabbit plasma were determined using the iodinated tracers.
IT 87026-18-4 87026-19-5 87026-20-8
87026-21-9
RL: ANT (Analyte); ANST (Analytical study)
(high-performance liquid chromatog. of)
RN 87026-18-4 CAPLUS
CN Prost-13-en-1-amide, 9,11,15-trihydroxy-N-[2-[2-(iodo-125I)-1H-imidazol-4-yl]ethyl]-6-oxo-, (9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 87026-19-5 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-N-[2-[2-(iodo-125I)-1H-imidazol-4-yl]ethyl]-6,9-dioxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L5 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 87026-20-8 CAPLUS
CN Prost-13-en-1-amide, 9,11-dihydroxy-N-[2-[2-(iodo-125I)-1H-imidazol-4-yl]ethyl]-6,15-dioxo-, (9α,11α,13E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 87026-21-9 CAPLUS
CN Prosta-5,13-dien-1-amide, 11,15-dihydroxy-N-[2-[2-(iodo-125I)-1H-imidazol-4-yl]ethyl]-9-oxo-, (5Z,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L5 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:461608 CAPLUS
DOCUMENT NUMBER: 95:61608
TITLE: Monodeuterated prostaglandins
INVENTOR(S): Bollingen, Pietro; Krieger, Manfred
PATENT ASSIGNEE(S): Sandoz A.-G., Switz.
SOURCE: U.S., 9 pp. Cont. of U.S. Ser. No. 914,401, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4259523	A	19810331	US 1979-37719	19790511
PRIORITY APPLN. INFO.:			US 1976-697403	A2 19760618
			US 1976-740182	A1 19761109
			US 1978-914401	A1 19780612

AB A series of known 15-deutero prostaglandins was prepared conventionally.
IT 62541-06-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 62541-06-4 CAPLUS
CN Prost-13-en-1-amide-15-d, N-[(8β)-9,10-didehydro-6-methylergolin-8-yl]-11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



L5 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:442470 CAPLUS
DOCUMENT NUMBER: 95:42470
TITLE: Prostanoic ergolin-8-yl esters, thioesters, and amides
INVENTOR(S): Wenger, Roland
PATENT ASSIGNEE(S): Sandoz A.-G., Switz.
SOURCE: U.S., 9 pp. Cont. of U.S. Ser. No. 773,663, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4249001	A	19810203	US 1979-55802	19790709
SE 7701916	A	19771028	SE 1977-1916	19770222
AU 7722819	A1	19780907	AU 1977-22819	19770301
PRIORITY APPLN. INFO.:			CH 1976-5268	A 19760427
			CH 1977-2059	A 19770218
			US 1977-773663	A1 19770302

OTHER SOURCE(S): MARPAT 95:42470
AB A series of known title compds. was prepared conventionally.
IT 65428-57-1P 65428-58-2P 65428-59-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65428-57-1 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-N-[[(8β)-6-methylergolin-8-yl]methyl]-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



RN 65428-58-2 CAPLUS
CN Prost-13-en-1-amide, N-[[(8β)-9,10-didehydro-6-methylergolin-8-

L5 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl]methyl]-11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



RN 65428-59-3 CAPLUS
CN Prostan-1-amide, N-[[(8β)-9,10-didehydro-6-methylergolin-8-yl]methyl]-11,15-dihydroxy-9-oxo-, (11α,15S)- (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1979:610969 CAPLUS
DOCUMENT NUMBER: 91:210969
TITLE: Ergolin-8-ylalkylesters, -thioesters and -amides of prostanoic acids
INVENTOR(S): Wagner, Roland
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Switz.
SOURCE: Ger. Offen., 39 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2803058	A1	19790726	DE 1978-2803058	19780125
PRIORITY APPLN. INFO.:			DE 1978-2803058 A	19780125

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A number of title compds. (e.g., I) were prepared by coupling the prostaglandin and ergoline components. Addition of the appropriate heterocycle to PGA analogs gave the 11α-heterocyclylprostaglandins, in turn converted into title compound analogs, such as II. In all, .apprx.60 compds. and intermediates were prepared

IT 65428-57-1P 65428-58-2P 65428-59-3P
65451-80-1P 71951-71-8P 71951-72-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 65428-57-1 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-N-[[(8β)-6-methylergolin-8-yl]methyl]-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



RN 65428-58-2 CAPLUS
CN Prost-13-en-1-amide, N-[[(8β)-9,10-didehydro-6-methylergolin-8-yl]methyl]-11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



RN 65428-59-3 CAPLUS
CN Prostan-1-amide, N-[[(8β)-9,10-didehydro-6-methylergolin-8-yl]methyl]-11,15-dihydroxy-9-oxo-, (11α,15S)- (9CI) (CA INDEX NAME)



RN 65451-80-1 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-N-[[(8α)-6-methylergolin-8-yl]methyl]-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



RN 71951-71-8 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-N-[2-[(8β)-6-methylergolin-8-yl]ethyl]-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 71951-72-9 CAPLUS
CN Prosta-5,13-dien-1-amide, 9,11,15-trihydroxy-N-[[(8β)-6-methylergolin-8-yl]methyl]-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

L5 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1979:574898 CAPLUS
DOCUMENT NUMBER: 91:174898
TITLE: N-(Tetrazol-5-yl)prostaglandin carboxamides
INVENTOR(S): Schaaf, Thomas Ken
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2901476	A1	19790719	DE 1979-2901476	19790116
DE 2901476	B2	19810604		
DE 2901476	C3	19820422		
DK 7805233	A	19790717	DK 1978-5233	19781123
IN 150279	A	19820904	IN 1978-DE841	19781123
CS 208109	P	19810831	CS 1978-8841	19781222
HU 26763	O	19830928	HU 1978-PI658	19781222
HU 184763	B	19841029		
DD 141155	C	19800416	DD 1978-210198	19781227
SU 831071	A3	19810515	SU 1978-2715902	19781227
PL 117869	B1	19810831	PL 1978-212183	19781227
JP 54100378	A2	19790808	JP 1979-2869	19790112
CA 1152502	A1	19830823	CA 1979-319536	19790112
BE 873471	A1	19790716	BE 1979-192890	19790115
FI 7900120	A	19790717	FI 1979-120	19790115
NO 7900122	A	19790717	NO 1979-122	19790115
SE 7900353	A	19790717	SE 1979-353	19790115
SE 427657	B	19830425		
SE 427657	C	19830804		
NL 7900292	A	19790718	NL 1979-292	19790115
AU 7943359	A1	19790726	AU 1979-43359	19790115
AU 507853	B2	19800228		
FR 2414503	A1	19790810	FR 1979-857	19790115
FR 2414503	B1	19811224		
ZA 7900149	A	19791227	ZA 1979-149	19790115
ES 476865	A1	19800101	ES 1979-476865	19790115
AT 7900275	A	19811215	AT 1979-275	19790115
AT 367755	B	19820726		
IL 56433	A1	19820430	IL 1979-56433	19790115
GB 2012272	B2	19821020	GB 1979-1428	19790115
CH 635833	A	19830429	CH 1979-380	19790115
ES 482421	A1	19800401	ES 1979-482421	19790711

PRIORITY APPLN. INFO.: US 1978-869569 A 19780116
US 1978-893731 A 19780405
US 1978-869469 A 19780116

OTHER SOURCE(S): MARPAT 91:174898
GI

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB I (A = ethylene or cis-vinylene, Q = ethylene or trans-vinylene, R = H or OH, R1 = CH2Ar, CH2OAr, or CR2R3Pr, R2 and R3 = H or Me) were prepared Thus, PGF2α 11,15-bis(tetrahydropyranyl ether) was treated with 1,1'-carbonyldiimidazole, and the product oxidized with Jones reagent and deprotected to give II.

IT 71746-89-9P 71746-91-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deprotection of)

RN 71746-89-9 CAPLUS

CN Prosta-5,13-dien-1-amide, 9-oxo-11,15-bis[(tetrahydro-2H-pyran-2-yl)oxy]-N-1H-tetrazol-5-yl-, (5Z,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 71746-91-3 CAPLUS

CN Prosta-5,13-dien-1-amide, 16,16-dimethyl-9-oxo-11,15-bis[(tetrahydro-2H-pyran-2-yl)oxy]-N-1H-tetrazol-5-yl-, (5Z,11α,13E,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 71746-92-4P 71746-93-5P 71746-94-6P
71746-95-7P 71746-96-8P 71746-97-9P
71746-98-0P 71746-99-1P 71747-00-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 71746-92-4 CAPLUS

CN Prosta-5,13-dien-1-amide, 9,11,15-trihydroxy-N-1H-tetrazol-5-yl-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 71746-93-5 CAPLUS

CN Prosta-5,13-dien-1-amide, 11,15-dihydroxy-9-oxo-N-1H-tetrazol-5-yl-, (5Z,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 71746-94-6 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-9-oxo-N-1H-tetrazol-5-yl-, (11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 71746-95-7 CAPLUS
CN 5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenylbutyl)-5-oxocyclopentyl]-N-1H-tetrazol-5-yl-, [1R-[1α(Z),2β(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 71746-96-8 CAPLUS
CN Cyclopentaneheptanamide, 3-hydroxy-2-(3-hydroxy-4-phenyl-1-butenyl)-5-oxo-N-1H-tetrazol-5-yl-, [1R-[1α,2β(1E,3S*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 71746-97-9 CAPLUS
CN 5-Heptenamide, 7-[3,5-dihydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)cyclopentyl]-N-1H-tetrazol-5-yl-, [1R-[1α(Z),2β(1E,3R*),3α,5α]]- (9CI) (CA INDEX NAME)



RN 71746-98-0 CAPLUS
CN 5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-1H-tetrazol-5-yl-, [1R-[1α(Z),2β(1E,3R*),3.alpha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 71746-99-1 CAPLUS
CN Prosta-5,13-dien-1-amide, 9,11,15-trihydroxy-16,16-dimethyl-N-1H-tetrazol-5-yl-, (5Z,9α,11α,13E,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 71747-00-7 CAPLUS
CN Prosta-5,13-dien-1-amide, 11,15-dihydroxy-16,16-dimethyl-9-oxo-N-1H-tetrazol-5-yl-, (5Z,11α,13E,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 71746-86-6P 71746-88-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, deprotection, and oxidation of)
RN 71746-86-6 CAPLUS
CN Prosta-5,13-dien-1-amide, 9-hydroxy-11,15-bis[(tetrahydro-2H-pyran-2-yl)oxy]-N-1H-tetrazol-5-yl-, (5Z,9α,11α,13E,15S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 71746-88-8 CAPLUS
CN Prosta-5,13-dien-1-amide, 9-hydroxy-16,16-dimethyl-11,15-bis[(tetrahydro-

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2H-pyran-2-yl)oxy]-N-1H-tetrazol-5-yl-, (5Z,9α,11α,13E,15R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1978:51072 CAPLUS
DOCUMENT NUMBER: 88:51072
TITLE: Ergolin-8-yl alkyl esters, thioesters, and amides of prostanoic acids
INVENTOR(S): Wenger, Roland
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Switz.
SOURCE: Ger. Offen., 39 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2707915	A1	19771117	DE 1977-2707915	19770224
DK 7700751	A	19771028	DK 1977-751	19770221
FI 7700572	A	19771028	FI 1977-572	19770222
GB 1577647	A	19801029	GB 1977-7981	19770225
ZA 7701215	A	19781025	ZA 1977-1215	19770301
NL 7702221	A	19771031	NL 1977-2221	19770302
BE 852055	A1	19770905	BE 1977-175449	19770303
JP 52131600	A2	19771104	JP 1977-22259	19770303
FR 2353549	A1	19771230	FR 1977-6181	19770303
SU 741794	D	19800615	SU 1977-2457126	19770303
FR 2355837	A1	19780120	FR 1977-26295	19770830

PRIORITY APPLN. INFO.: CH 1976-5268 A 19760427

AB Treatment of prostaglandin E1 with dihydroisolysergylamine gave 11α,15S-dihydroxy-9-oxo-13-trans-prostenoic acid dihydroisolysergylamide. Similarly prepared were 59 alkyl esters, thio esters, and other ergolinyl amides of prostenoic acids.

IT 65428-53-7P 65428-57-1P 65428-58-2P
65428-59-3P 65451-80-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 65428-53-7 CAPLUS
CN Prost-13-en-1-amide, N-[2-[(8β)-9,10-didehydro-6-methylergolin-8-yl]ethyl]-11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 65428-57-1 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-N-[[(8β)-6-methylergolin-8-yl]methyl]-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



RN 65428-58-2 CAPLUS
CN Prost-13-en-1-amide, N-[[(8β)-9,10-didehydro-6-methylergolin-8-yl]methyl]-11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



RN 65428-59-3 CAPLUS
CN Prostan-1-amide, N-[[(8β)-9,10-didehydro-6-methylergolin-8-yl]methyl]-11,15-dihydroxy-9-oxo-, (11α,15S)- (9CI) (CA INDEX NAME)



RN 65451-80-1 CAPLUS
CN Prost-13-en-1-amide, 11,15-dihydroxy-N-[[(8α)-6-methylergolin-8-yl]methyl]-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:170946 CAPLUS
DOCUMENT NUMBER: 86:170946
TITLE: Prostaglandins containing a hydroxy group and a deuterium atom on the carbon atom in position 15
INVENTOR(S): Bollinger, Pietro; Krieger, Manfred
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 37 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2626582	A1	19770303	DE 1976-2626582	19760614
DK 7602701	A	19761226	DK 1976-2701	19760616
FI 7601741	A	19761226	FI 1976-1741	19760616
SE 7606972	A	19761226	SE 1976-6972	19760617
NO 7602102	A	19761228	NO 1976-2102	19760617
NL 7606709	A	19761228	NL 1976-6709	19760621
GB 1560902	A	19800213	GB 1976-25886	19760622
BE 843318	A1	19761223	BE 1976-168237	19760623
FR 2316930	A1	19770204	FR 1976-19091	19760623
FR 2316930	B1	19781117		
DD 124727	C	19770309	DD 1976-193532	19760623
IL 49889	A1	19791130	IL 1976-49889	19760623
CA 1095032	A1	19810203	CA 1976-255572	19760623
JP 52003039	A2	19770111	JP 1976-73923	19760624
AT 7604604	A	19820115	AT 1976-4604	19760624
ZA 7603810	A	19780222	ZA 1976-3810	19760625
AU 511527	B2	19800821	AU 1976-15326	19760625
FR 2351974	A1	19771216	FR 1977-1972	19770125
FR 2351974	B1	19800814		

PRIORITY APPLN. INFO.: CH 1975-8250 A 19750625

GI



I



II

AB A series of deuterated prostaglandins, e.g., I, was prepared conventionally;

L5 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
the D was introduced by redn. of conventional intermediates, such as II, with Zn borodeuteride.
IT 62541-06-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 62541-06-4 CAPLUS
CN Prost-13-en-1-amide-15-d, N-[(8β)-9,10-didehydro-6-methylergolin-8-yl]-11,15-dihydroxy-9-oxo-, (11α,13E,15S)- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:43438 CAPLUS
DOCUMENT NUMBER: 84:43438
TITLE: Prostadienoic acid amide derivatives
INVENTOR(S): Inukai, Noriyoshi; Murakami, Masuo; Iwamoto, Hidenori;
Tamura, Toshinari; Yanagizawa, Isao; Hasegawa, Osamu; Ishii, Yoshio; Matsuda, Hideya
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50013363	A2	19750212	JP 1973-64571	19730608

PRIORITY APPLN. INFO.: JP 1973-64571 A 19730608

GI For diagram(s), see printed CA Issue.
AB The amide derivs. I (R = H, lower alkyl, R1 = H or protecting group, R2 = OH, NH2, lower alkoxy, Z1 = residue of amino acid or peptide from which terminal NH2 and CO2H were removed) were prepared by the reaction of II (R3 = H or protecting group) or their derivs. with H2NZ1COR4 (III; R4 = OH, NH2, lower alkoxy), followed by hydrolysis in acidic or alkaline media if necessary. I had biol. activities similar to PGE2 and PGF2α (no data). Thus, 55.6 mg ClCO2Et and 51.8 mg Et3N were added to a solution of 267.9 mg II [R = H, R3 = tetrahydropyran-2-yl, (15S), Z = CHOH] in 3 ml CHCl3 at -5 to 0°, the mixture stirred 20-30 min, a solution of 71.6 mg ethyl glycinate and 51.8 mg Et3N in 4 ml CHCl3 added, the mixture stirred 2 hr at room temperature, treated with CHCl3, aqueous NaHCO3, H2O, and anhydrous Na2SO4 to give 342.9 mg crude I (R1 = tetrahydropyran-2-yl, R2 = OEt, Z = CHOH, Z1 = CH2); this in 6 ml AcOH-H2O-THF (19:11:3 in volume) was hydrolyzed at 40 ± 2° to give 179.8 mg I (R1 = H, other symbols same as before), which in 10 ml MeOH and 2 ml THF was hydrolyzed under N in the presence of 1.23 ml 1N NaOH at room temperature to give 105.4 mg I [R = R1 = H, R2 = OH, Z = CHOH, Z1 = CH2, (15S)]. Among 7 addnl. I similarly prepared were (R, R1, R2, Z, and Z1 given): Me, H, OH, CHOH, CH2; H, H (15S), tert-BuO, CO, CH2; H, H (15S), NH2, CHOH, CH2; H, H (15S), MeO, CHOH, CHCH2OH.
IT 57931-45-0P 57973-23-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57931-45-0 CAPLUS
CN L-Tryptophan, N-[(5Z,11α,13E,15S)-11,15-dihydroxy-1,9-dioxoprosta-5,13-dien-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 57973-23-6 CAPLUS
CN L-Tryptophan, N-[(5Z,9α,11α,13E,15S)-9,11,15-trihydroxy-1-oxoprosta-5,13-dien-1-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	78.03	250.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.25	-11.25

STN INTERNATIONAL LOGOFF AT 09:44:26 ON 23 OCT 2006